Affiliation:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Abstract
Low survival rates in children with recurrent medulloblastoma (MB) necessitate the search for new therapeutic approaches as alternatives to the existing treatment standards. Favorable dosimetric characteristics of stereotactic radiation techniques justify the use of such treatments for local radiation control in children with oligometastatic recurrent MB. Given the constant risk of metastatic dissemination and in order to potentiate response to radiation therapy and improve progression-free survival, metronomic molecular-targeted antiangiogenic therapy (MEMMAT, Medulloblastoma European Multitarget Metronomic AntiAngiogenic Trial) can be considered in children with recurrent/progressive MB. Here, we report 2 clinical cases that demonstrate the effectiveness of the treatment approach involving stereotactic irradiation followed by the metronomic MEMMAT regimen for oligometastatic recurrent MB in pediatric patients. The patients’ parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
Publisher
Fund Doctors, Innovations, Science for Children
Reference7 articles.
1. Sabel M., Fleischhack G., Tippelt S., Gustafsson G., Doz F., Kortmann R., et al.; SIOP-E Brain Tumour Group. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129(3):515-524.
2. Gaab C., Adolph J.E., Tippelt S., Mikasch R., Obrecht D., Mynarek M., et al. Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers 2022, 14,471.
3. Simon S Lo, Achilles J Fakiris, Ramzi Abdulrahman, Mark A Henderson, Eric L Chang, John H Suh & Robert D Timmerman (2008) Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in pediatric brain tumors, Expert Review of Neurotherapeutics, 8:1, 121-132, DOI: 10.1586/14737175.8.1.121
4. Robison N.J., Campigotto F., Chi S.N., Manley P.E., Turner C.D., Zimmerman M.A., et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014 Apr; 61(4): 636-42.
5. Peyrl A., Chocholous M., Slavc I., André N., Kieran M.W., Azizi A.A. A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma MEMMAT (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial). ClinicalTrials.gov Identifier: NCT01356290.